Drug Trial Radar · NCT07086755
Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury
Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,100
Planned (sponsor's estimate)
Start
Oct 23, 2025
Primary completion
May 31, 2031
Study completion May 31, 2031
Sponsor
- Lead sponsor
- Paul PotnuruAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Akebia Therapeutics
- First posted
- Jul 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the efficacy and safety of vadadustat for treating hospitalized patients with nonintubated Acute Respiratory Distress Syndrome (ARDS) secondary to pathogen-associated lung injury.
Conditions
- Nonintubated Acute Respiratory Distress Syndrome (ARDS)
- Pathogen-associated Lung Injury
Interventions
Vadadustat 900mgDrug
Participants will receive 900mg vadadustat (as oral tablets) daily for 14 days or until the date of discharge, whichever comes first, at approximately the same time each day without regard for timing of meals.
Vadadustat 1200mgDrug
Participants will receive 1200mg vadadustat (as oral tablets) daily for 14 days or until the date of discharge, whichever comes first, at approximately the same time each day without regard for timing of meals.
PlaceboDrug
Participants will matching placebo (as oral tablets) daily for 14 days or until the date of discharge, whichever comes first, at approximately the same time each day without regard for timing of meals.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Win ratio for hierarchical composite endpoint based on death, duration of mechanical ventilation or ECMO, and duration of high-flow nasal oxygenation or non-invasive ventilationTime frame: from the time of enrollment to 28 days after enrollment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The University of Texas Health Science Center at Houston
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.